PERIOPERATIVE HEPARIN-THERAPY INHIBITS LATE DEATH FROM METASTATIC CANCER
Low-dose heparin prophylaxis reduces postoperative death from fatal pulmonary embolism and its long-term anti-cancer effect has now been assessed in a retrospective study of 1250 patients, 336 of whom (30%) underwent operation for cancer. There was a striking reduction in three year
mortality amongst those patients who received low dose heparin compared to unteated controls (7.6% vs. 12.5%, P=0.005). Death from disseminated malignancy was halved (9.2% vs. 21.4%). The mechanism remains unclear, but may reflect either the antithrombotic actions of heparin or a direct antitumour
cell effect.
Document Type: Research Article
Affiliations: PRINCE WALES HOSP,BRIDGEND,M GLAM,WALES. THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND.
Publication date: 01 April 1995
- The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content